Transaction DateRecipientSharesTypePriceValue
14th September 2020Glen Tullman23Open or private sale$124.46$2,862.58
14th September 2020Lee Shapiro23Open or private sale$124.46$2,862.58
11th September 2020Glen Tullman36,576Other acquisition or disposition$0.00
11th September 2020Lee Shapiro395,025Other acquisition or disposition$0.00
11th September 2020Glen Tullman312,511Other acquisition or disposition$0.00
11th September 2020Glen Tullman395,025Other acquisition or disposition$0.00
11th September 2020Glen Tullman58,773Other acquisition or disposition$0.00
11th September 2020Lee Shapiro58,773Other acquisition or disposition$0.00
11th September 2020Lee Shapiro36,576Other acquisition or disposition$0.00
11th September 2020Glen Tullman65,081Other acquisition or disposition$0.00
Livongo Health
Livongo Health logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Livongo Health, Inc. develops and operates a consumer digital health platform. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008.


Ticker: LVGO
Sector: Technology Services
Industry: Packaged Software
SEC Central Index Key (CIK): 1639225
Employees: 615
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $686 M (0%)
Inventory, Net: $18 M (-39%)
Other Assets, Current: $0 (-100%)
Assets, Current: $951 M (95%)
Property, Plant and Equipment, Net: $16 M (0%)
Other Assets, Noncurrent: $569 Th (0%)
Assets: $1 B (87%)
Accounts Payable, Current: $6 M (-23%)
Accrued Liabilities, Current: $36 M (0%)
Liabilities, Current: $48 M (14%)
Other Liabilities, Noncurrent: $397 Th (-86%)
Liabilities: $471 M (785%)
Common Stock, Value, Issued: $100 Th (5%)
Retained Earnings (Accumulated Deficit): $171 M (0%)
Stockholders' Equity (Parent): $578 M (0%)
Liabilities and Equity: $1 B (87%)
Revenue: $92 M (-42%)
Cost of Revenue: $21 M (-45%)
Gross Margin: $70 M (-41%)
Research and Development: $16 M (-46%)
Sales and Marketing: $33 M (-45%)
General and Administrative Expenses: $22 M (-41%)
Operating Income/Loss: $262 Th (-96%)
Provision for income taxes: $72 Th (-22%)